<DOC>
	<DOC>NCT01085084</DOC>
	<brief_summary>The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5mg /day and 1mg /day) in active lupus arthritis patients. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. For Multiple Sclerosis.</brief_summary>
	<brief_title>Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>1. Subjects diagnosed with SLE. 2. Subjects with active lupus arthritis as evident by At least 4 tender and 4 swollen joints Active synovitis â‰¥ 1 joint with some loss of functional range of movement 1. Subjects with severe renal impairment or dialysis 2. Severe, unstable and/or progressive CNS lupus 3. Subjects with a clinically significant or unstable medical or surgical condition 4. Women who are pregnant or nursing or who intend to be during the study period. 5. Women of childbearing potential who do not practice an acceptable method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus (SLE)</keyword>
	<keyword>Lupus Arthritis</keyword>
	<keyword>Laquinimod</keyword>
</DOC>